Home
Acelyrin, Inc.

Acelyrin, Inc. Market Share Analysis for June 2026

building a sustainable biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines.

Health > Biotechnology and Pharmaceuticals

Domainacelyrin.com

Year Founded2020

Employees51 - 200

Annual Revenue--

Acelyrin, Inc.

Acelyrin, Inc. (including company regionals)

acelyrin.com

See more website traffic and engagement information

Total visits to Acelyrin, Inc.'s top domains

Understand Acelyrin, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Acelyrin, Inc.'s top domains

Analyze Acelyrin, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Acelyrin, Inc.'s top domains

See how Acelyrin, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Acelyrin, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Acelyrin, Inc.

These are the website technologies, by industry, used by Acelyrin, Inc. top domains

Advertising (2)

PubMatic

Audio Video Media (2)

YouTube

Conversion & Analytics (2)

Google Analytics

Email Services (1)

Microsoft Exchange Online

More Technologies

6

See all

News & Signals from Acelyrin, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMarciniak left Acelyrin, Inc on Jan 1st '26.An experienced international biopharma leader, Mr. Marciniak joins Transcenta from ACELYRIN Inc, where he led similar efforts for the company's private-to-public transition including support for its USD 300 million Series C financing, all-stock acquisition of ValenzaBio, USD 621 million initial public offering, and eventual acquisition by Alumis Inc. earlier this year.

NewsAlumis Inc. partnered with Acelyrin, Inc on Feb 6th '25.On February 6, 2025, Alumis Inc. announced a merger agreement with ACELYRIN, Inc., creating a combined company dedicated to developing transformative therapies for immune-mediated diseases.

NewsGil Labrucherie left Acelyrin, Inc as Chief Financial Officer on Jan 2nd '24.Acelyrin said that Chief Financial Officer Gil Labrucherie has resigned and will be leave on Jan. 2 to pursue another opportunity.